Mylan Beats Securities Class Action Over EpiPen, Generic Drugs

Mylan N.V. and several of its current and former officers shook off a securities class action alleging the drug manufacturer misled investors by hiding violations of regulatory and antitrust law.

The investors alleged that Mylan’s statements about the market and its income were misleading because the company was involved in antitrust conspiracies related to its EpiPen.

The EpiPen competition claims alleged Mylan’s negotiations with pharmacy benefit managers were monopolistic or injurious to competition. The investors asserted that Mylan misled them by failing to alert them that its place in the market was based on antitrust violations.

The claims fail because ...